CN101707882A - PDGFRβ特异性抑制剂 - Google Patents

PDGFRβ特异性抑制剂 Download PDF

Info

Publication number
CN101707882A
CN101707882A CN200880012257A CN200880012257A CN101707882A CN 101707882 A CN101707882 A CN 101707882A CN 200880012257 A CN200880012257 A CN 200880012257A CN 200880012257 A CN200880012257 A CN 200880012257A CN 101707882 A CN101707882 A CN 101707882A
Authority
CN
China
Prior art keywords
antibody
seq
pdgfrβ
antibodies
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880012257A
Other languages
English (en)
Chinese (zh)
Inventor
Z·朱
J·沈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of CN101707882A publication Critical patent/CN101707882A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fuel Cell (AREA)
CN200880012257A 2007-04-17 2008-04-17 PDGFRβ特异性抑制剂 Pending CN101707882A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92397907P 2007-04-17 2007-04-17
US60/923,979 2007-04-17
PCT/US2008/005137 WO2008130704A2 (en) 2007-04-17 2008-04-17 PDGFRβ-SPECIFIC INHIBITORS

Publications (1)

Publication Number Publication Date
CN101707882A true CN101707882A (zh) 2010-05-12

Family

ID=39837443

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880012257A Pending CN101707882A (zh) 2007-04-17 2008-04-17 PDGFRβ特异性抑制剂

Country Status (14)

Country Link
US (3) US7740850B2 (enExample)
EP (1) EP2139921A2 (enExample)
JP (1) JP5209702B2 (enExample)
KR (1) KR101136262B1 (enExample)
CN (1) CN101707882A (enExample)
AU (1) AU2008242444B2 (enExample)
BR (1) BRPI0810374A2 (enExample)
CA (1) CA2682390A1 (enExample)
EA (1) EA019595B1 (enExample)
IL (1) IL200779A0 (enExample)
MX (1) MX2009011226A (enExample)
NZ (1) NZ579734A (enExample)
UA (1) UA99608C2 (enExample)
WO (1) WO2008130704A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CN104936614A (zh) * 2013-01-09 2015-09-23 瑞泽恩制药公司 抗-PDGFR-β抗体及其使用
CN107353342A (zh) * 2011-12-05 2017-11-17 X 博迪生物科学公司 PDGF受体β结合多肽
CN109021104A (zh) * 2017-06-12 2018-12-18 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
CN113166249A (zh) * 2018-10-05 2021-07-23 首尔大学校产学协力团 Pdgf受体抗体及其用途
CN115335403A (zh) * 2020-02-07 2022-11-11 毕欧丽安技术有限公司 血小板衍生生长因子受体（pdgfr）抗体、其缀合物、组合物及用途
WO2025209170A1 (zh) * 2024-04-02 2025-10-09 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604280A3 (en) * 2008-03-27 2013-10-16 ZymoGenetics, Inc. Compositions and methods for inhibiting PDGFRBETA and VEGF-A
AU2009242587B2 (en) * 2008-04-30 2015-05-28 Strike Bio, Inc. Highly pure plasmid DNA preparations and processes for preparing the same
US20120231537A1 (en) * 2008-04-30 2012-09-13 Gradalis, Inc. Highly Pure Plasmid DNA Preparations
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
WO2010069913A1 (en) 2008-12-16 2010-06-24 Novartis Ag Yeast display systems
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
WO2011036305A2 (en) * 2009-09-28 2011-03-31 Medizinische Universität Wien New use of pdgfrbeta inhibitors
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
ES2926988T3 (es) 2011-03-15 2022-10-31 X Body Inc Métodos de cribado de anticuerpos
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
CA2980385A1 (en) 2015-03-20 2016-09-29 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Pericyte long non-coding rnas
PL3389636T3 (pl) 2015-12-16 2022-11-28 Regeneron Pharmaceuticals, Inc. Kompozycje i metody wytwarzania mikrocząstek białkowych
WO2017106609A2 (en) * 2015-12-16 2017-06-22 Kadmon Corporation, Llc. Pdgfr beta antibody
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
RU2770590C2 (ru) * 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
WO2019165982A1 (en) 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
DE102018204828A1 (de) 2018-03-29 2019-10-02 Ford Global Technologies, Llc Verhinderung von Glatteis durch Abwasser von Kraftfahrzeugen
US11773155B2 (en) 2018-08-09 2023-10-03 Beijing Wisdomab Biotechnology Co., Ltd Bispecific antibody against rabies virus, and application thereof
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6259971B1 (en) * 1997-06-30 2001-07-10 Compaq Computer Corporation Portable fuel-cell-powered system with ultrasonic atomization of H2O by-product
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2001090192A2 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1325531B1 (de) * 2000-09-22 2004-06-09 Siemens Aktiengesellschaft Verfahren zum überwachen des medienaustritts aus einer brennstoffzelle und brennstoffzellenanlage
EP1313161A1 (en) * 2001-11-15 2003-05-21 Ballard Power Systems AG Fuel cell system and method for operating the same
US7582726B2 (en) * 2003-11-10 2009-09-01 Ghc Research Development Corporation VEGF receptor antagonists
JP2008512352A (ja) 2004-07-17 2008-04-24 イムクローン システムズ インコーポレイティド 新規な四価の二重特異性抗体
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N A LOKKER ET AL.: "Functional importance of platelet-derivedgrowth factor(PDGF) receptor extracellular immunoglobulin-like domains", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CN107353342A (zh) * 2011-12-05 2017-11-17 X 博迪生物科学公司 PDGF受体β结合多肽
TWI640537B (zh) * 2011-12-05 2018-11-11 Ｘ 染色體有限公司 ＰＤＧＦ受體β結合多肽
CN104936614A (zh) * 2013-01-09 2015-09-23 瑞泽恩制药公司 抗-PDGFR-β抗体及其使用
CN109021104A (zh) * 2017-06-12 2018-12-18 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
CN113166249A (zh) * 2018-10-05 2021-07-23 首尔大学校产学协力团 Pdgf受体抗体及其用途
CN113166249B (zh) * 2018-10-05 2024-09-24 首尔大学校产学协力团 Pdgf受体抗体及其用途
US12098206B2 (en) 2018-10-05 2024-09-24 Seoul National University R&Db Foundation PDGF receptor antibody and use thereof
CN115335403A (zh) * 2020-02-07 2022-11-11 毕欧丽安技术有限公司 血小板衍生生长因子受体（pdgfr）抗体、其缀合物、组合物及用途
WO2025209170A1 (zh) * 2024-04-02 2025-10-09 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用

Also Published As

Publication number Publication date
AU2008242444B2 (en) 2013-05-02
KR101136262B1 (ko) 2012-07-05
US20110207005A1 (en) 2011-08-25
EA019595B1 (ru) 2014-04-30
NZ579734A (en) 2012-01-12
CA2682390A1 (en) 2008-10-30
WO2008130704A3 (en) 2008-12-24
AU2008242444A1 (en) 2008-10-30
KR20090130382A (ko) 2009-12-23
IL200779A0 (en) 2010-05-17
UA99608C2 (en) 2012-09-10
US7740850B2 (en) 2010-06-22
WO2008130704A2 (en) 2008-10-30
MX2009011226A (es) 2010-04-01
JP5209702B2 (ja) 2013-06-12
EA200970953A1 (ru) 2010-10-29
JP2010524466A (ja) 2010-07-22
US20090053241A1 (en) 2009-02-26
BRPI0810374A2 (pt) 2014-10-29
US20100221267A1 (en) 2010-09-02
EP2139921A2 (en) 2010-01-06

Similar Documents

Publication Publication Date Title
US7740850B2 (en) PDGFRβ-specific antibodies
CN108368174B (zh) 用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
CN101102791B (zh) 抗血管内皮生长因子受体-1的抗体
AU2009228158B2 (en) Compositions and methods for inhibiting PDGFRbeta and VEGF-A
JP5769969B2 (ja) Ａｘｌ抗体
JP5719298B2 (ja) 組換え抗上皮増殖因子受容体抗体組成物
CN101612399B (zh) 用作治疗继发性骨肿瘤的抗PDGFRα抗体
JP2011505120A5 (enExample)
EP2411407A1 (en) Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
CN101918579A (zh) 完全人抗-vegf抗体和使用方法
JP2014501725A (ja) Ｈｇｆを標的とする多特異的抗原結合タンパク質
CN102006885A (zh) 完全人源抗vegf抗体及其使用方法
AU2009299787A2 (en) Anti CXCR4 antibodies and their use for the treatment of cancer
JP2008508858A (ja) マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
CN114729053B (zh) 一种4-1bb结合蛋白及其应用
CN101233155B (zh) 人抗表皮生长因子受体抗体
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
WO2017175054A1 (en) Anti-vegfr-1 antibodies and uses thereof
HK1115302B (en) Antibodies against vascular endothelial growth factor receptor-1

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100512